抗糖尿病薬の市場規模、シェア、動向分析レポート：薬剤クラス別、糖尿病タイプ別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

抗糖尿病薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の抗糖尿病薬市場規模は2030年までに1,685億5,000万米ドルに達し、2025～2030年のCAGRは10.75%で拡大すると予測されています。

糖尿病の有病率の増加がこの市場の主要促進要因です。不規則な食生活や肥満の増加も、対象疾患の罹患率を誘発することで製品需要を押し上げると予想されます。現在パイプラインにある製品の将来的な商業化と、アジア太平洋とラテンアメリカ新興市場における大きな未開拓機会の存在が、今後の市場成長を促進すると予想されます。

インスリンは最も収益性の高いセグメントであり、その市場規模は2013年に200億米ドルを超えました。インスリンは、この市場で最も有利なセグメントの一つでもあります。より高い有効性を示す新製品の導入と、政府の有利なイニシアチブの存在が、市場の魅力を高める要因となっています。

抗糖尿病薬市場のレポートハイライト

• 新たに承認されたジャヌビア、ネシーナ、オングリザなどのDPP-4阻害剤は、1日1回の投与レジメンと安全性プロファイルが評価され、急速に市場に浸透しました。
• 北米は、2024年に市場の41.48%を占め、最も成熟した抗糖尿病薬市場であったインスリン製剤やその他の抗糖尿病薬の高い市場浸透率と、洗練された償還制度の存在が、同地域の市場成長を牽引すると予想されます。
• アジア太平洋は、メーカーに有利な将来の成長機会をもたらすと期待されています。アンメットニーズが多く存在し、医療インフラが急速に改善されていることが、同地域の市場成長を促進する要因として期待されています。また、現地メーカーによる安価な製品の導入も市場を牽引すると期待されています。
• 抗糖尿病薬の主要市場参入企業には、AstraZeneca plc、Bayer AG、武田薬品工業、Eli Lilly and Company、Boehringer Ingelheim、Bristol-Myers Squibb Company、Merck & Co.Inc.、Johnson & Johnson Services Inc.、Pfizerがあります。
• 市場は寡占的な性質を持っており、少数の企業が市場の70％以上を占めています。新製品開発を目的とした広範な研究開発投資と、政府との契約を通じた市場への参入が、これらの企業が採用する主要持続可能性戦略です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場系統の展望
• 市場動向と展望
• 市場力学
  • 糖尿病罹患率の上昇
  • 調査と技術の進歩
  • 意識の向上と早期介入
• 市場抑制要因分析
  • 高い開発コスト
  • 副作用と安全性の懸念
• 産業分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
• 価格分析
• パイプライン分析

第4章 抗糖尿病薬市場：薬剤クラスのビジネス分析

• 薬剤クラス市場シェア、2024年と2030年
• 薬剤クラスセグメントダッシュボード
• 市場規模と予測と動向分析（薬剤クラス別、2018～2030年）
• インスリン
• GLP-1受容体作動薬
• DPP-4阻害剤
• SGLT2阻害剤
• DPP-4阻害剤
• その他

第5章 抗糖尿病薬市場：糖尿病タイプのビジネス分析

• 糖尿病タイプ市場シェア、2024年と2030年
• 糖尿病タイプセグメントダッシュボード
• 市場規模、予測、動向分析（糖尿病タイプ別、2018～2030年）
• タイプ1
• タイプ2

第6章 抗糖尿病薬市場：投与経路のビジネス分析

• 投与経路市場シェア、2024年と2030年
• 投与経路セグメントダッシュボード
• 市場規模、予測、動向分析（投与経路別、2018～2030年）
• 経口
• 皮下
• 静脈内

第7章 抗糖尿病薬市場：流通チャネルのビジネス分析

• 流通チャネル市場シェア、2024年と2030年
• 流通チャネルセグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• オンライン薬局
• 病院薬局
• 小売薬局

第8章 抗糖尿病薬市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Johnson & Johnson Services Inc.
  • Boehringer Ingelheim
  • Novartis AG
  • Takeda Pharmaceutical Company
  • Bayer AG

List of Tables

• Table 1 List of abbreviations
• Table 2 Global antidiabetics market, by drug class, 2018 - 2030 (USD Million)
• Table 3 Global antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 4 Global antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 5 Global antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 Global antidiabetics market, by region, 2018 - 2030 (USD Million)
• Table 7 North America antidiabetics market, by country, 2018 - 2030 (USD Million)
• Table 8 North America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 9 North America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 10 North America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 11 North America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 U.S. antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 13 U.S. antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 14 U.S. antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 15 U.S. antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 16 Canada antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 17 Canada antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 18 Canada antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 19 Canada antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Mexico antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 21 Mexico antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 22 Mexico antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 23 Mexico antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Europe antidiabetics market, by country, 2018 - 2030 (USD Million)
• Table 25 Europe antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 26 Europe antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 27 Europe antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 28 Europe antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 29 UK antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 30 UK antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 31 UK antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 32 UK antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33 Germany antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 34 Germany antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 35 Germany antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 36 Germany antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 France antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 38 France antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 39 France antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 40 France antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 41 Italy antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 42 Italy antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 43 Italy antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 44 Italy antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45 Spain antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 46 Spain antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 47 Spain antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 48 Spain antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 49 Denmark antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 50 Denmark antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 51 Denmark antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 52 Denmark antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 53 Sweden antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 54 Sweden antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 55 Sweden antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 56 Sweden antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 57 Norway antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 58 Norway antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 59 Norway antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 60 Norway antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific antidiabetics market, by country, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 66 Japan antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 67 Japan antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 68 Japan antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 69 Japan antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70 China antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 71 China antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 72 China antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 73 China antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 India antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 75 India antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 76 India antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 77 India antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 78 Australia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 79 Australia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 80 Australia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 81 Australia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 82 Thailand antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 83 Thailand antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 84 Thailand antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 85 Thailand antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 86 South Korea antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 87 South Korea antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 88 South Korea antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 89 South Korea antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Latin America antidiabetics market, by country, 2018 - 2030 (USD Million)
• Table 91 Latin America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 92 Latin America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 93 Latin America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 94 Latin America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 95 Brazil antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 96 Brazil antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 97 Brazil antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 98 Brazil antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 99 Argentina antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 100 Argentina antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 101 Argentina antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 102 Argentina antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 103 Middle East & Africa antidiabetics market, by country, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 108 South Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 109 South Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 110 South Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 111 South Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 116 UAE antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 117 UAE antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 118 UAE antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 119 UAE antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
• Table 120 Kuwait antidiabetics market, by drug type, 2018 - 2030 (USD Million)
• Table 121 Kuwait antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
• Table 122 Kuwait antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
• Table 123 Kuwait antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Antidiabetics market segmentation
• Fig. 8 Market snapshot, 2024
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's five forces analysis
• Fig. 14 Market penetration & growth prospect mapping, 2022
• Fig. 15 Global antidiabetics market: drug class movement analysis
• Fig. 16 Global antidiabetics market, for Insulin, 2018 - 2030 (USD Million)
• Fig. 17 Global antidiabetics market, for GLP-1 receptor agonists, 2018 - 2030 (USD Million)
• Fig. 18 Global antidiabetics market, for DPP- 4 inhibitors, 2018 - 2030 (USD Million)
• Fig. 19 Global antidiabetics market, for SGLT2 inhibitors, 2018 - 2030 (USD Million)
• Fig. 20 Global antidiabetics market, for others, 2018 - 2030 (USD Million)
• Fig. 21 Global antidiabetics market: diabetes type movement analysis
• Fig. 22 Global antidiabetics market, for type 1, 2018 - 2030 (USD Million)
• Fig. 23 Global antidiabetics market, for type 2, 2018 - 2030 (USD Million)
• Fig. 24 Global antidiabetics market: route of administration movement analysis
• Fig. 25 Global antidiabetics market, for oral, 2018 - 2030 (USD Million)
• Fig. 26 Global antidiabetics market, for subcutaneous, 2018 - 2030 (USD Million)
• Fig. 27 Global antidiabetics market, for intravenous, 2018 - 2030 (USD Million)
• Fig. 28 Global antidiabetics market: distribution channel movement analysis
• Fig. 29 Global antidiabetics market, for online pharmacies, 2018 - 2030 (USD Million)
• Fig. 30 Global antidiabetics market, for hospital pharmacies, 2018 - 2030 (USD Million)
• Fig. 31 Global antidiabetics market, retail pharmacies, 2018 - 2030 (USD Million)
• Fig. 32 Regional marketplace: Key takeaways
• Fig. 33 Regional outlook, 2024 & 2030
• Fig. 34 Global antidiabetics market: region movement analysis
• Fig. 35 North America antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 36 U.S. antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 37 Canada antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 38 Mexico antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 39 Europe antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 40 Germany antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 41 UK antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 42 France antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 43 Italy antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 44 Spain antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 45 Denmark antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 46 Sweden antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 47 Norway antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 48 Asia Pacific antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 49 Japan antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 50 China antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 51 India antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 52 Australia antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 53 South Korea antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 54 Thailand antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 55 Latin America antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 56 Brazil antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 57 Argentina antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 58 Middle East and Africa antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 59 South Africa antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 60 Saudi Arabia antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 61 UAE antidiabetics market, 2018 - 2030 (USD Million)
• Fig. 62 Kuwait antidiabetics market, 2018 - 2030 (USD Million)

Antidiabetics Market Growth & Trends:

The global antidiabetics market size is expected to reach USD 168.55 billion by 2030, expanding at a CAGR of 10.75% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights:

• The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
• North America was the most mature antidiabetics market in 2024 accounting for over 41.48% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
• Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
• Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
• The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Diabetes Type
  • 1.2.3. Distribution Channel
  • 1.2.4. Route of Administration
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis:
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Rising Diabetes Prevalence
  • 3.3.2. Advancements in Research and Technology
  • 3.3.3. Increasing Awareness and Early Intervention
• 3.4. Market Restraint Analysis
  • 3.4.1. High Development Costs
  • 3.4.2. Side Effects and Safety Concerns
• 3.5. Industry Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis
• 3.6. Pricing Analysis
• 3.7. Pipeline Analysis

Chapter 4. Antidiabetics Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Insulin
  • 4.4.1. Insulin Market, 2018 - 2030 (USD Million)
    • 4.4.1.1. Insulin Market, By Type
      • 4.4.1.1.1. Long-acting insulin
        • 4.4.1.1.1.1. Long-acting insulin market, 2018 - 2030 (USD Million)
      • 4.4.1.1.2. Premix insulin
        • 4.4.1.1.2.1. Premix insulin market, 2018 - 2030 (USD Million)
      • 4.4.1.1.3. Fast-acting insulin
        • 4.4.1.1.3.1. Fast-acting insulin market, 2018 - 2030 (USD Million)
      • 4.4.1.1.4. Human insulin
        • 4.4.1.1.4.1. Human insulin market, 2018 - 2030 (USD Million)
• 4.5. GLP-1 Receptor Agonists
  • 4.5.1. GLP-1 Receptor Agonists Market, 2018 - 2030 (USD Million)
• 4.6. DPP- 4 Inhibitors
  • 4.6.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.7. SGLT2 Inhibitors
  • 4.7.1. SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.8. DPP-4 Inhibitors
  • 4.8.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Antidiabetics Market: Diabetes Type Business Analysis

• 5.1. Diabetes Type Market Share, 2024 & 2030
• 5.2. Diabetes Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Diabetes Type , 2018 to 2030 (USD Million)
• 5.4. Type 1
  • 5.4.1. Type 1 Market, 2018 - 2030 (USD Million)
• 5.5. Type 2
  • 5.5.1. Type 2 Market, 2018 - 2030 (USD Million)

Chapter 6. Antidiabetics Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Subcutaneous
  • 6.5.1. Subcutaneous Market, 2018 - 2030 (USD Million)
• 6.6. Intravenous
  • 6.6.1. Intravenous Market, 2018 - 2030 (USD Million)

Chapter 7. Antidiabetics Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Online Pharmacies
  • 7.4.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Hospital Pharmacies
  • 7.5.1. Hospital Pharmacies, Market, 2018 - 2030 (USD Million)
• 7.6. Retail Pharmacies
  • 7.6.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Antidiabetics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Antidiabetics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novo Nordisk
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Eli Lilly and Company
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Sanofi
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Merck & Co., Inc.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. AstraZeneca plc
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Johnson & Johnson Services Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Boehringer Ingelheim
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Novartis AG
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Takeda Pharmaceutical Company
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Bayer AG
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives